A Phase Ib/II Study of Pembrolizumab and Monoclonal Antibody Therapy in Patients With Advanced Cancer (PembroMab
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 29 Jun 2017
At a glance
- Drugs Pembrolizumab (Primary) ; Cetuximab; Trastuzumab; Trastuzumab emtansine
- Indications Solid tumours
- Focus Adverse reactions
- 23 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 08 Dec 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Oct 2017, according to ClinicalTrials.gov record.
- 26 Dec 2014 New trial record